|Day Low/High||100.71 / 103.40|
|52 Wk Low/High||72.06 / 112.88|
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
This list is not a buy list but a list of stocks that have been brought to new heights.
A weekly close above $92 sets ABC up in a great position.
Here's how to play the stock now.
Shares of AmerisourceBergen haven't been this cheap since the dark days of 2009.
Shares of ABC found buying interest in the $72-$70 area in late December and again in April.
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Cardinal Health and McKesson have similar business models, but they are very different stocks.
Straying from these names could land you in quicksand as the 4th quarter begins.
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
Buy Cardinal Health and give it time for the market to reassess the industry.
These stocks are selling at historically low earnings multiples, but have raised their dividends for decades.
A fresh look at the charts and indicators of ABC seems timely.
The Wall Street Journal reported that Walgreens Boots Alliance has contacted AmerisourceBergen about a possible takeover.
With Dow futures pointed south, it looks to be another interesting day on Wall Street. Here's what you need to know.
Maybe inverse and/or leveraged positions are perverse in nature.
It's hard to understand the magnitude of the change.
These names are showing technical characteristics of either bullish or bearish reversal patterns.
AmerisourceBergen is a high-quality name that offers a ray of value in a pricey market.
An observation: Despite being within 1% of the all-time high in the S&P Index, this week's feature was a number of investment potholes --relatively large sized individual fundamental disappointments followed by marked stock price drops. Celgene , B...
Akorn and AmerisourceBergen are both flashing big moves, but in which direction is unclear.
Demographics will continue to favor health-care and pharmaceutical companies.